SonoVascular, Inc.
Luke Harada is the Chief Operating Officer at SonoVascular, Inc., leading the development of innovative medical technology aimed at treating venous and arterial diseases. Since 2022, Luke has also provided strategic advisory consulting services through OneMedTech Advisors LLC. Previously, Luke held key leadership roles in corporate development at prominent medical device companies such as Hillrom, BD, and CR Bard, where responsibilities included mergers and acquisitions, as well as business development initiatives. Additional experience includes serving as an Investment Partner at Mitsui & Co. Global Investment and various roles at Johnson & Johnson, where significant achievements included securing a worldwide exclusive license for the CYPHER™ drug-eluting stent. Luke's career commenced at Merrill Lynch & Co., where leadership in M&A and strategic advisory was demonstrated. Luke holds a JD from Northwestern University Pritzker School of Law, an MBA from Northwestern University Kellogg School of Management, and a BA in Economics from Harvard University.
This person is not in any teams
SonoVascular, Inc.
SonoVascular has developed a novel pharmaco-mechanical ultrasound facilitated thrombectomy system, SonoThrombectomy™, that utilizes microbubble-mediated cavitation as a core enabling mechanism of action to remove blood clots more effectively. The system uniquely combines: (i) ultrasound, (ii) microbubbles, (iii) low dose thrombolytic drug, and (iv) mechanical retrieval and aspiration, delivered via an integrated intravascular catheter system. SonoVascular’s technology has been engineered to address and overcome the deficiencies and limitations of current interventional devices. Its design enables safe and effective treatment in the catheterization laboratory (cathlab), maximizes the reduction in clot burden, enhances the delivery and reduces the dose and duration of thrombolytics to levels that optimize safety and effectiveness, and eliminates the need for patients to be treated in the ICU.